Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88